相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A coalition of advocacy groups and community leaders is urging Wake County commissioners to block the proposed $2 billion merger between WakeMed and Atrium Health, citing risks of higher healthcare costs and reduced charity care. - A Brown University School of Public Health report warns that cross-market hospital mergers like this one have been linked to price increases of 7% to 17% for patients. - Opponents argue Atrium's financial assistance policy is narrower than WakeMed's, potentially limiting coverage for non-urgent but medically necessary services for low-income patients. - WakeMed executives and supporters contend the merger will expand specialty care, add over 3,000 local jobs, and strengthen the county's safety-net hospital system.
- Mirvetuximab soravtansine's successful development has validated the potential of antibody-drug conjugates (ADCs) in ovarian cancer treatment, paving way for second-generation agents. - Emerging ADC luveltamab tazevibulin and other novel candidates with diverse warhead mechanisms are showing encouraging progress in clinical development. - Researchers are focusing on understanding resistance mechanisms and optimal therapeutic sequencing as multiple ADC options become available for ovarian cancer treatment.
- AD109, a combination of aroxybutynin and atomoxetine, represents the first oral pharmacologic therapy targeting neurological pathways to activate upper airway dilator muscles in obstructive sleep apnea. - Phase II MARIPOSA trial demonstrated significant efficacy with 77% of mild OSA patients achieving AHI scores below 10, while 42% of moderate cases reached this threshold. - The ongoing SynAIRgy Phase III trial is enrolling 640 participants who cannot tolerate CPAP therapy, with primary endpoint measuring 50% reduction in apnea-hypopnea index over 26 weeks. - Treatment showed statistically significant improvements in daytime fatigue and was well-tolerated with no serious adverse events in earlier trials.
